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FOREWORD 
 
The Trent  Working Group on Acute Purchasing was set up to enable purchasers to share 
research knowledge about the effectiveness and cost-effectiveness of acute service 
interventions and determine collectively their purchasing policy. The Group is facilitated by 
The School of Health and Related Research (ScHARR), part of the Trent Institute for Health 
Services Research, the ScHARR Support Team being led by Professor Ron Akehurst and 
Dr Nick Payne, Consultant Senior Lecturer in Public Health Medicine. 
 
The process employed operates as follows. A list of topics for consideration by the Group is 
recommended by the purchasing authorities in Trent and approved by the Health Authority 
and Trust Chief Executives (HATCH) and the Trent Development and Evaluation Committee 
(DEC). A public health consultant from a purchasing authority leads on each topic assisted 
by a support team from ScHARR, which provides help including literature searching, health 
economics and modelling. A seminar is led by the public health consultant on the particular 
intervention where purchasers and provider clinicians consider research evidence and agree 
provisional recommendations on purchasing policy. The guidance emanating from the 
seminars is reflected in this series of Guidance Notes which have been reviewed by the 
Trent DEC, chaired by Professor Sir David Hull. 
 
In order to share this work on reviewing the effectiveness and cost-effectiveness of clinical 
interventions, The Trent Institute’s Working Group on Acute Purchasing has joined a wider 
collaboration, InterDEC, with units in other regions. These are: The Wessex Institute for 
Health Research and Development, The Scottish Health Purchasing Information Centre 
(SHPIC) and The University of Birmingham Department of Public Health and Epidemiology. 
 
 
 
 
 
 
 
Professor R L Akehurst 
Chairman, Trent Working Group on Acute Purchasing 
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EXECUTIVE SUMMARY 
 
Multiple myeloma is a neoplastic disorder characterised by the uncontrolled proliferation and 
accumulation of malignant plasma cells within the bone marrow. Prognosis for myeloma 
patients is very poor, with median survival of around three years and less than 5% of 
patients alive at 10 years. Myeloma is associated with high morbidity resulting from 
anaemia, infections, bone pain and renal failure. Plateau duration is an extremely important 
clinical end-point as it is associated with low morbidity, few symptoms and better quality of 
life. 
 
Current standard treatments for myeloma are based on combinations of chemotherapy for 
all except a sub-set of patients with early stage disease. Because of the lack of progress 
with conventional chemotherapy regimens, there has been a move towards using higher 
doses of chemotherapy to combat chemoresistance. The doses of drugs used in high dose 
chemotherapy (HDC) cause irreversible bone marrow toxicity and require patients to have 
follow-up blood support with either bone marrow transplantation (BMT) or with peripheral 
blood stem cell transplantation (PBCT). Due to the high median age of myeloma patients, 
only around 30% will be eligible for HDC with autologous BMT or PBCT. For patients aged 
under 55 for whom a suitable donor can be found, allogeneic transplantation is the clinical 
treatment of choice. There are approximately 2,800 registrations of multiple myeloma in 
England and Wales each year, approximately 5.5 per 100,000 population per annum (Office 
of National Statistics - ONS). There were 253 cases of myeloma reported in the Trent 
Region in 1994. 
 
The Intergroupe Francais du Myelome (IFM) randomised controlled trial reported complete 
remission rates of 22% and median event-free survival of 27 months in patients treated with 
HDC and autologous BMT. This compares with only 5% of patients achieving complete 
remission, and median event-free survival of 18 months in the conventional chemotherapy 
arm. Improved complete remission rates and improved event-free and overall survival were 
also reported by smaller phase II studies. The overall survival and EFS benefits based on 
the results of the IFM trial were both eight months, based on trial data alone. Overall survival 
benefit for patients under 60 was slightly higher at around nine months. 
 
The estimated cost of HDC procedure for myeloma patients is £12,460, while the estimated 
standard chemotherapy cost for myeloma patients is £1,980. The cost per life year gained 
(LYG) for HDC in myeloma is estimated to be £14,970, based on trial data alone. Sensitivity 
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analysis results indicate that inclusion of five year projected benefits could increase the 
number of LYG to 1.7, with a cost per LYG of £6,160. 
 
HDC patients tend to have a better quality of life in remission and, thus, require fewer 
hospital admissions than those treated with conventional chemotherapy. Inclusion of long-
term follow-up costs may decrease the marginal cost of HDC. Benefits from HDC will be 
considerably greater than those reported if quality of life issues are considered. Inclusion of 
quality of life indices is likely to increase the benefits and reduce the cost per LYG figures 
based on overall survival only. 
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1.  INTRODUCTION 
1.1  Background to Disease 
 
Multiple myeloma is a neoplastic disorder characterised by the uncontrolled proliferation and 
accumulation of malignant plasma cells within the bone marrow, and further distinguished by 
the production of monoclonal immunoglobulin (Ig).  
 
Normally, less than 5% of cells in the normal bone marrow are plasma cells, and these 
produce immunoglobulins as part of the immune response to infection. Plasma cell numbers 
are markedly increased in myeloma due to malignant transformation. These are 
accompanied, in the majority of cases, by excessive Ig production with concurrent 
suppression of normal antibody production. Morbidity results from the myeloma cell mass 
and Ig overproduction, leading to anaemia, increased infections, lytic bone disease and 
renal failure. Quality of life issues are especially important, because, when uncontrolled, the 
clinical picture is one of recurrent hospital admissions with severe bone pain, infections or 
fractures, and the need for regular blood transfusions and palliative radiotherapy. 
 
This disease remains incurable with standard chemotherapy; less than 5% of subjects live 
longer than 10 years.
1
 Newer combinations of chemotherapy have also failed to improve 
true complete remission beyond 5%. Objective responses (partial remission), defined as a 
reduction in serum or urine protein and marrow plasma cells, can be achieved in 50-60% of 
subjects with conventional chemotherapy. Unfortunately, median event-free survival or 
plateau phase and overall survival typically do not exceed 18 and 36 months respectively. 
Plateau duration, however, is an extremely important clinical endpoint as it is associated 
with low morbidity, few symptoms and better quality of life.  
 
The low incidence of complete remission with conventional therapy suggests marked drug 
resistance, even in newly diagnosed disease, and has prompted evaluation of dose intensity 
in attempts to overcome drug resistance in myeloma patients. Transplantation of 
haemopoietic stem cells (obtained from bone marrow or blood) accelerates restoration of 
marrow recovery and enables the use of much higher doses of chemotherapy with or 
without total body irradiation. Such approaches are currently being explored in respect of 
reported improvements in complete remission rates and event-free and overall survival.
2
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1.2   Aetiology and Incidence 
 
The origins of the disease remain unknown. However, the rising incidence in those less than 
55 suggests that environmental factors such as radiation exposure, agro-chemical exposure 
and antigeneic stimulation may have a causative role.
3
 
 
Median age at diagnosis is 70 years, although the incidence in younger subjects is 
increasing.
3
 The disease accounts for 1% of all cancers, though 10-15% of haematological 
malignancies.
1
 
 
Figure 1  Trent Age/ Sex Registrations for Myeloma 1985 - 1994 
Registrations of Myeloma in the Trent Region 1985 - 1994
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Source: Trent Cancer Registry 
 
There were 2,810 registrations of multiple myeloma in England and Wales in 1991, with a 
rate per 100,000 population per annum of 5.8 for males and 5.1 for females.
4
 There were 
253 cases of myeloma reported in the Trent Region in 1994 (117 male, 136 female). Crude 
incidence rates for Trent in 1994 were 5 per 100,000 per annum for males and 5.6 per 
100,000 per annum for females.
5
 (Figure 2 refers). 
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Figure 2  Trent Myeloma Incidence Rates 1985 - 1994 
Annual Registrations of Myeloma per 100,000 Population for Trent Region
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Source: Trent Cancer Registry 
 
1.3   Prognosis and Mortality 
 
Careful evaluation of individuals with stratification into low risk, or high risk groups with 
poorer long-term outcome, is essential. In 1975, Durie and Salmon
6
 developed a staging 
system that is still widely used and divides patients into stage I, II or III on the basis of 
clinical parameters and myeloma cell mass (i.e. haemoglobin levels, serum calcium, bone 
disease). The three stages are sub-classified into A or B depending upon the absence or 
presence of renal failure.  
 
Stage I low cell mass (<0.6 x 10
12
 cells/m
2
 ) 
Stage II intermediate cell mass (0.6 - 1.2 x 10
12
 cell /m
2
 ) 
Stage III high cell mass ( >1.2 x 10
12
 cells /m
2
 ) 
Sub-classification  A: serum creatinine value  170 mol/ l) 
   B: serum creatinine value  170 mol/ l) 
(Source: International Myeloma Foundation) 
 
Several new prognostic factors have been identified, including 2 microglobulin (2-M), C-
reactive protein, and the plasma cell labelling index.
7
 At present, no one factor estimates 
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individual survival consistently. Nonetheless, such evaluations are important, given the wide 
range of survival.
8
 Overall prognosis is poor, with around 50% survival at one year (Tables I 
and 2).  Numbers of  myeloma deaths in Trent between 1985 and 1994 are shown in Figure 
3. 
 
Table 1  Median Survival for Multiple Myeloma by Stage
9
 
 
Stage I > 60 months 
Stage II 41 months 
Stage III 23 months 
 
Table 2  Relative Survival Estimates (Based on Cases Newly Diagnosed in 1988) 
 
Myeloma 1 year 3 year 5 year 
Male 47% 24% 15% 
Female 55% 33% 24% 
(Source: Trent Cancer Registry) 
 
Figure 3  Annual Myeloma Deaths in the Trent Region 1985-1994 
Number of Deaths due to Myeloma Registered in the Trent Region 1985 - 1994
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1.4   Treatment Options 
 
Oral alkylating agents, especially melphalan, and radiotherapy, have been the mainstay of 
therapy for myeloma, with the exception of indolent disease where close observation is 
recommended. The introduction of newer combination regimens improve response, but this 
is not translated into a major survival improvement
10
 (Figure 3 refers). Alternative modes of 
drug administration, particularly continuous infusions of adriamycin and vincristine and 
pulses of high dose corticosteroids (vincristine/doxorubicin/dexamethasone - VAD, 
vincristine/adriamycin/methylprednisolone - VAMP) result in higher response rates, up to 
20% of cases enter complete remission
11
.  Again, responses are not durable, but such 
therapies produce rapid disease response and do not damage stem cells, enabling 
autologous marrow collection.  
 
McElwain and Powles
12
 demonstrated a dose-response effect in vivo using high dose 
melphalan, with a high response rate (complete remission of up to 35%), but at the price of 
severe bone marrow depression and significant treatment related mortality (TRM). This 
prompted the use of high dose chemotherapy (HDC) (with or without total-body irradiation) 
followed by an infusion by allogeneic or autologous stem cells to rescue patients from the 
severe haematological toxicity of HDC.
13
 
 
In suitable subjects, initial disease control with combination chemotherapy is followed by 
stem cell harvest, prior to consolidation therapy with HDC and haemopoietic support. Such 
therapy has a high response rate, with improved quality of life and a median overall survival 
of 4 to 5 years.
14
  
 
1.5 Scale of Problem in a ‘Typical’ District 
 
In a ‘typical’ district of 500,000 people, approximately 27 newly reported cases of multiple 
myeloma would be expected each year. Myeloma accounts for around 200 deaths in the 
Trent Region per annum (Office of National Statistics - ONS). 
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In order to treat all eligible patients with HDC, the additional costs to a ‘typical’ health 
authority of HDC over initial conventional chemotherapy costs would be around £120,000 
per annum. Current practice suggests over half of eligible patients are already receiving 
HDC and, thus, the extra costs required would be around £60,000. However, in some health 
authorities a smaller proportion of eligible patients is being treated with HDC. (See Section 3 
for more detailed discussion of likely costs). 
 
1.6  European Blood and Marrow Transplant Registry  
 
The European Blood and Marrow Transplant Registry (EBMT) is a collaborative group 
established in the 1980s.  The aims of the EBMT include: 
 Collection of clinical data on patients undergoing HDC; 
 Sponsorship of large clinical trials in HDC; 
 Development of minimum standards and accreditation guidelines for HDC. 
 
The EBMT includes a number of sub-groups with responsibility for the major tumour types 
commonly treated with HDC, e.g. lymphoma, solid tumours, leukaemias, paediatric 
malignancies etc. 
 
In the UK, a subsidiary group, The British Society for Blood and Marrow Transplantation 
(BSBMT) has recently been established. Membership of the EBMT and BSBMT is voluntary. 
There is no obligation on clinicians to register their data with these organisations.  However, 
there is a general consensus that, given the morbidity, mortality and cost implications of 
these treatments, patients not in clinical trials should have their data recorded. Data from 
the EBMT for 1996 are now available and show the commonest uses of HDC. 
 
EBMT guidelines advocate allogeneic bone marrow transplantation (alloBMT) in multiple 
myeloma preferably in patients up to the age of 55 who have responded to first-line 
treatment, or before second-line treatment in subjects resistant to first-line treatment. 
Allogeneic transplantation with sibling donors may be considered for selected patients. 
Transplantation with unrelated donors should only be considered on a ‘developmental’ 
basis.  Autologous transplantation (ABMT) is an option for patients below 65 years of age 
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who respond to first-line treatment. These guidelines are currently in draft form, but are 
generally endorsed and are likely to be accepted. 
 
Table 3   HDC Notifications from EBMT Data in 1996 
Disease  Notifications 
Non-Hodgkin’s Lymphoma (NHL) 2,645 
Breast Cancer 2,156 
Acute Myeloid Leukaemia (AML) 1,878 
Myeloma 1,856 
Chronic Myeloid Leukaemia (CML) 1,382 
Acute Lymphoblastic Leukaemia (ALL) 1,275 
Hodgkin's disease  739 
 
 
Table 4 EBMT Proposed Classification of Transplant Procedures for Myeloma - 
1998 
 EBMT DRAFT RECOMMENDATIONS 
 
 Local Clinical 
Interpretation 
Disease Status Allogeneic - 
Sibling 
Allogeneic - 
Unrelated 
Autologous Autologous 
Myeloma Stage I CRP NR CRP CRP 
 Other CRP       D R R 
 
CRP  To be undertaken in approved Clinical 
Research Protocols 
 R In routine use for selected patients 
D    Developmental  NR Not generally recommended 
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2.   THE USE OF HIGH DOSE CHEMOTHERAPY IN THE TREATMENT OF 
MULTIPLE MYELOMA: SUMMARY OF EVIDENCE OF EFFECTIVENESS 
 
2.1 Introduction to Treatment in Multiple Myeloma  
 
Conventional chemotherapy cures few, if any, patients (Figure 4 refers). 
 
Figure 4  Overall Survival Results with Conventional Chemotherapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Alexanian and Dimopoulos (1994)
10
 
N.B. The graph uses a logarithmic scale for survival 
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This failure of standard chemotherapy, together with demonstrations of a dose-dependent 
response to chemotherapy provide the rationale for HDC. Extensive phase II studies with 
myeloablative therapy followed by stem cell rescue, support the notion that ‘more is better’, 
effecting complete remission rates of 40-50% with event-free survival and overall survival of 
the order of three and five years respectively, when performed early in the disease. Patients 
achieving a complete remission had an absence of bone pain with markedly improved 
performance status and quality of life.
13,15
 
 
On the basis of this evidence, HDC is becoming standard treatment for a select group of 
patients. There is currently regional variation regarding the use of HDC, with specialist 
centres often treating patients with HDC and District General Hospitals entering patients into 
the ongoing Medical Research Council (MRC) trial. Only around 30% of all myeloma 
patients will be eligible for HDC, of whom around 50% within the Trent region will be 
currently receiving the treatment. This would result in around 5-10 patients per annum for a 
‘typical’ district within Trent. 
 
2.2   Treatment Eligibility 
 
Autologous transplantation has been offered to patients up to 70 years of age, but is 
associated with a higher treatment related mortality over 60. Given the high median age of 
patients with multiple myeloma, it is estimated that only around 30% are suitable for HDC. 
 
Allogeneic bone marrow transplantation (alloBMT) can only be applied to young patients, 
usually under 50, with human leukocyte antigen (HLA) -identical siblings. It also carries a 
risk of graft-versus-host disease.
16
 Consequently, it is currently limited to about 5% of cases 
and most receive autologous transplants following HDC.  
 
2.3    Autologous Versus Allogeneic Transplantation 
 
AlloBMT offers the advantage of a lack of tumour cell contamination and a graft-versus-
myeloma effect.
17
 The major problem with alloBMT has been the very high treatment related 
mortality. While alloBMT results in a lower relapse rate than autografting, treatment related 
mortality following an allograft is much higher (13% with autologous compared with  41% 
with allogeneic). Consequently, in a pair-mate analysis with 63 autotransplants, overall 
survival was superior in the autotransplant group.
18
 Recent studies suggest decreased 
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procedural mortality and better survival if transplantation is undertaken early (40% versus 
20%).
19,20
 Newer lower intensity allograft procedures may also reduce TRM.
21
  
 
2.4 Survival following Allogeneic Transplant 
Importantly, the survival curve in alloBMT beyond five years approaches a plateau (compare 
with figure 4), and alloBMT is probably the only genuinely curative approach in myeloma at 
present. As such, it is argued that this approach should be considered in preference to an 
autologous procedure in newly diagnosed myeloma patients under 50 years of age. 
 
Figure 5  Overall Survival Results with Allogeneic Transplant 
This study involved a heterogeneous group of myeloma patients. Survival is reported as 
time after BMT, which could be several months post-diagnosis. 
 
 
MULTICENTRE EBMT REGISTRY STUDY 
 
 
 
 
 
 
 
 
 
 
Source: Gahrton et al. (1991)
22
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2.5 Assessment of Trial Results 
2.5.1    Single Autologous Transplantation 
 
Several uncontrolled studies of HDC followed by autologous marrow or peripheral blood 
stem cell transplantation (PBCT) have been reported. Collectively, these show highly 
encouraging increased remission and survival rates, with low treatment related mortality and 
improved quality of life.
13,23
 These findings have been confirmed by a recent prospective 
randomised trial.
14
 This is the only randomised controlled trial (RCT) for the use of HDC with 
BMT for myeloma patients. 
 
2.5.2  Randomised Studies 
 
Attal et al. (1996) - Intergroupe Francais du Myelome (IFM) - study of ABMT Versus 
HDC in Myeloma.
14
   
200 newly diagnosed patients, aged under 65, with stage II/III multiple myeloma were 
randomised to receive either vincristine/melphalan/cyclophosphamide/prednisolone or 
vincristine/carmustine/dexorubicin/prednisolone (VMCP/BVAP) combination chemotherapy 
for 12 months, or HDC which consisted of 4-6 cycles of VMCP/BVAP followed by an 
autograft (ABMT). 
 
Analysis on an intention to treat basis showed that HDC resulted in significantly superior 
complete remission (22% versus 5%), as well as projected five year event-free survival 
(28% versus 10%) and overall survival (52% versus 12%) as compared with standard 
therapy (Table 5). Treatment-related mortality was similar. Median follow-up was 37 months 
in the conventional arm and 41 months in the HDC arm.  
 
Table 5  Survival and Remission Rates for IFM Randomised Trial 
Outcome Conventional 
Chemotherapy 
High Dose Therapy 
& ABMT 
p-value 
Median EFS 18 months 27 months  
Median OS 37 months not yet reached   
5 year event-free survival 10% 28% p=0.01 
5 year overall survival 12% 52% p=0.03 
Complete remission 5% 22%  
Very good partial response 9% 16%  
Progressive disease 25% 12%  
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Benefits of HDC were most marked in patients under 60 years of age, with 70% probability 
of five year overall survival compared to 18% for conventional therapy. However, only 58% 
of those over 60 completed intensive treatment. There was no significant survival advantage 
for HDC in patients over 60.
24
 
 
This trial appears to provide the strongest evidence to date for HDC in patients aged 60 and 
under. 
 
2.6 Ongoing Trials 
Further randomised studies are currently in progress in the UK (MRC Myeloma VII) and in 
the USA (US Intergroup Study).  MRC Myeloma VII is the largest study to date, where newly 
diagnosed subjects with myeloma, under 65 years of age, are randomly assigned to 
conventional therapy or HDC with autologous stem cell support. Cost-effectiveness and 
quality of life issues are also being addressed. Recruitment problems have been 
encountered by the MRC due to early reporting of results of the IFM trial,
14
 which led many 
centres to consider the case sufficiently proven. As such, it is difficult to know when the trial 
will report. 
 
The US Intergroup study has recently been modified in the light of the IFM results, however, 
with the previously optional PBSC collection after induction therapy now mandatory. Hence, 
the objective of this study is now whether an early transplant is superior to salvage therapy. 
 
2.6.1 Non-randomised Studies  
Several non-randomised studies of newly diagnosed patients receiving conventional 
chemotherapy followed by HDC and an autograft have been reported (Table 6 refers). 
Collectively, these demonstrate that complete remission rates increase from about 5% with 
standard therapy to about 40% with myeloablative therapy, and overall survival varied 
between 2.7 and 6.7 years. Treatment related mortality is low (2% to 11%). These studies 
confirm the efficacy and safety of HDC with autologous stem cell transplantation. Thus far, 
no study has shown that conventional therapy is better, and overall survival is consistently 
higher than the median survival of around 2 - 2.5 years using conventional chemotherapy 
(see Figure 4). 
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Table 6 Phase II Studies of HDC in the Treatment of Multiple Myeloma  
Author Patient 
Nos. 
Median 
Age 
(Years) 
Follow-
up  
(Years) 
Complete 
Remission 
(%) 
Median 
Event-Free 
Survival 
(Years) 
Median 
Overall 
Survival 
(Years) 
Cunningham, 1994
25
 53 52 2.6 75% 2 6.7 
Anderson, 1993
26
 52 49 NA 40% 2.6 4.2 
Bjorkstrand, 1995
27
 207 49 NA 46% 2.4 2.7 
Harousseau, 1995
23
 133 52 3 37% 2 3.8 
Fermand, 1995
28
 63 44 7.5 20% 3.6 6.4 
Powles, 1997
29
 112 NA NA 53% 2.3 6.6 
Jagannath, 1996
30
 
 
231 51 3 37% 3.6 5.2 
NA-not available 
 
2.7 Double Autologous Transplantation 
Despite increased complete remission rates and improved prognosis, disease relapse 
remains a problem and a double autograft procedure has been used as an alternative 
strategy to intensify treatment.
11
  Two retrospective analyses, conducted exploring tandem 
transplants, have shown an increase in rates of partial and complete remission. 
 
2.7.1 Double Transplantation Versus Conventional Chemotherapy. 
Barlogie et al., 1997: Superiority of tandem autologous transplantation over standard 
therapy for previously untreated multiple myeloma.
11
  
In a pair-mate analysis, the outcome of 123 patients under 70 years of age with 
symptomatic multiple myeloma receiving ‘total therapy’ was compared to that of patients in 
the Southwest Oncology Group (SWOG) treated with standard therapy. Total therapy 
consisted of VAD induction chemotherapy, followed by a stem cell harvest, further 
combination chemotherapy and then high dose melphalan with stem cell rescue. Three to 
six months later, responding patients received a second autograft. 76% of patients 
completed total therapy, with a 4% treatment-related mortality in the first year.  
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116 pair-mates, matched for age, creatinine and 2M, were selected from both total therapy 
and 1,123 SWOG patients. As in the IFM randomised study, total therapy, analysed on an 
intention to treat basis, was superior to standard therapy, with a higher partial remission rate 
(85% compared with 52%), longer median event-free survival (49 versus 20 months, 
p=.0001) and overall survival (62+ versus 46 months, P=.003). Of patients completing two 
autografts, 48% achieved a complete remission. 
 
Vesole et al., 1996: Double autotransplants in myeloma.
31
 
This analysis of 496 subjects, from a single centre, enrolled into clinical trials of double 
transplantation, demonstrated that this approach was feasible up to 70 years of age. 363 
patients (73%) completed the second transplant. The complete remission rate increased 
from 24% to 43% following the second transplant, while the non-response rate fell from 32% 
to 19%. Regardless of pre-transplant biological factors, median overall survival exceeded 
5.5 years where transplantation was undertaken within 12 months of diagnosis and the 
second procedure followed within six months of the first. 
 
2.7.2 Double Versus Single Transplantation 
This apparently greater cytoreduction has prompted an IFM randomised trial comparing one 
versus two transplants. Early analysis of 200 patients shows a complete remission of 32% 
with 74% overall survival at two years (Attal et al., unpublished), but no clear difference, at 
present, between the groups. Clearly, the impact of such aggressive strategy needs further 
evaluation.  
 
2.8 When to Transplant 
 
The optimal timing of autologous transplantation remains to be determined. Transplantation 
was performed as part of initial therapy in the IFM study.
14
 Whether delayed autograft, at the 
time of disease progression, is also of benefit, requires further clarification by ongoing trials, 
such as the US Intergroup study. 
 
French investigators have randomised 185 patients to receive HDC and PBCT either early, 
or late, as a salvage strategy following relapse after VAMP chemotherapy.
24
 Preliminary 
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results suggest an equivalent outcome in terms of overall survival, but early HDC was 
associated with a longer period of treatment, suggesting a clinical benefit for this approach. 
Median event-free survival was 39 months with an estimated overall survival of 58 months.  
 
Results of uncontrolled studies indicate that autologous transplantation is a useful salvage 
therapy for primary refractory disease, although of limited value in resistant relapse.
31
 
 
2.9 Source of Autologous Stem Cells 
 
Autologous stem cells can be obtained from both autologous bone marrow transplantation 
and peripheral blood stem cell transplantation. The source of autologous stem cells had no 
significant impact on long-term results.
23
 PBCT is currently preferred, however, because of 
more rapid haemopoietic recovery. Furthermore, peripheral blood stem cell harvests can be 
performed on an out-patient basis, avoiding the morbidity of anaesthesia and marrow 
harvesting. The speed and degree of haematopoietic engraftment is related to the duration 
of prior therapy and is readily predicted by the quantity of CD 34 stem cells mobilised.
32
 
 
Contamination of the autologous graft remains a concern, with clonal B cells present in both 
sources of autograft.
33
 This has led to attempts to reduce such tumour cells either by 
negative purging or by the use of positive selection based on CD 34 antigen expression.
34
 
CD 34-selection does reduce the level of contamination in the reinfused product, but it is not 
yet known whether this leads to a lower relapse risk. Randomised studies addressing this 
issue are in progress.  
 
2.10  Summary 
 
Multiple myeloma, when uncontrolled, is characterised by frequent hospital admissions with 
severe bone pain, fractures, and infections. This, together with the requirement for blood 
product support and palliative radiotherapy, results in a poor quality of life for many patients. 
Conventional chemotherapy has failed thus far to make major inroads into disease outcome. 
Some progress has, at last, been achieved by a 'more is better' approach. For many, 
conventional chemotherapy is still the only possibility; however, high dose therapy with stem 
cell support is feasible in about 30% of cases and undoubtedly produces a more dramatic 
anti-myeloma effect with a better quality of remission.  
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The role of HDC in the first-line treatment of patients with multiple myeloma appears well 
established with the Attal
14
 randomised trial providing clear overall and event-free survival 
advantages. The role of HDC as a double transplant procedure may potentially provide even 
greater patient benefit. However, this remains to be proven by randomised trial. 
 
Analysis of the current data indicates that HDC with haemopoietic support, when compared 
to conventional treatment, shows: 
 increased survival (52% vs 12% at 5 years; p=0.03);
14
 
 increased plateau duration (28% vs 10% at 5 years, p=0.01);
14
 
 improved performance status and quality of life;
13,15
 
 low treatment-related mortality.
3,14
 
The indications are that this treatment should be introduced early in the course of the 
disease. 
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3.  COST AND BENEFIT IMPLICATIONS OF ADOPTING INTERVENTION 
 
3.1 General 
 
This economic analysis is based on RCT data using single transplantation following HDC. 
The principal trial on which it is based is the IFM
14
 which gives outcomes of both overall 
survival and event-free survival at 15, 30, 45 and 60 months. Using these data, the benefits 
have been estimated in terms of overall survival and progression-free survival comparing 
conventional chemotherapy with HDC supported by transplant.  
 
Area under the curve techniques have been used to estimate clinical benefit. This approach 
has a number of advantages: 
 
 it allows the experience of the whole cohort to be considered; 
 it removes the potential bias of median point estimates (as relative risk can change over 
time); 
 median point outcomes are not always achieved during the trial period; 
 median point estimates considerably underestimate the benefits in treatments which 
have high initial mortality, but in which survival curves later reach a plateau. (See Figure 
5). 
 
3.1.1 Benefits of Single Transplantation Following HDC in Multiple Myeloma 
 
Using these curve estimates, it is predicted that the marginal event-free survival benefit of 
HDC over standard chemotherapy in the treatment of multiple myeloma is approximately 
eight months (32 months c.f. 24 months).  
 
This estimate is taken as the difference between the area under the curve up to the end of 
the trial results, in this case 60 months. This may undervalue gains, as any benefit of the 
HDC arm is assumed to cease at the end of the trial period. 
 
Similar estimates have been made for overall survival, for all patients and also for patients 
aged 60 and under.  
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Figure 6 Attal IFM study
14
 - Event-free Survival Curve - All Patients 
 
 
 
 
 
 
 
 
 
 
Figure 7  Attal IFM Study - Overall Survival Curve - All Patients 
 
 
 
 
 
 
 
 
 
Using these curve estimates, it is predicted that the marginal overall survival benefit of HDC 
over standard chemotherapy is approximately eight months (44 months c.f. 36 months). 
Again, the additional benefits of HDC are assumed to cease at the end of the trial period. 
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Figure 8  Attal IFM Study - Overall Survival Curve- Patients <60 Years of Age 
 
 
 
 
 
 
 
 
 
 
 
In patients aged 60 years and under, the marginal overall survival benefit of HDC over 
standard chemotherapy is approximately nine months (48 cf. 39 months). 
 
3.1.2.  Benefits of HDC in Terms of Quality of Life  
These benefit analyses consider only the years of life and years of event-free survival 
gained; they make no allowance for the improved quality of life experienced by those 
receiving HDC. Quality of life issues, although difficult to quantify, are important because 
when uncontrolled, the clinical picture is one of recurrent hospital admissions with bone 
pain, fractures or infections. 
 
Although it is generally recognised that patients who respond to HDC tend to have a better 
quality of life than those patients treated with conventional chemotherapy, there is little 
published evidence quantifying these benefits in terms of quality of life. Small studies have 
reported improved quality of life for patients receiving HDC, with over two years excellent 
quality life years gained and a return to normal life and work for a proportion of the 
patients.
15 
This improvement in quality of life is reflected in local autologous transplant 
patients, of whom around 50% returned to work. 
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Quality of life measures have not been considered by trials reported to date, but will be 
included within the MRC trial. However, this trial is currently still recruiting and data will not 
be available for a number of years. 
 
3.2 Treatment Costs for Multiple Myeloma 
3.2.1  Cost of HDC Therapy for Multiple Myeloma 
Information on the relative cost of treatment for myeloma has been provided by the finance 
department at Central Sheffield University Hospitals NHS Trust. The main areas of 
difference between standard chemotherapy and HDC are the need for a harvesting 
procedure and the requirement for in-patient care for the latter.  
 
The contract costs for the HDC are based on pre-HDC chemotherapy estimated at £990, a 
3-4 week in-patient stay in a haematology ward, estimated at £8,420, plus six day visits at 
£200 per day and additional drug costs of £1,850. This results in a total cost for the high 
dose procedure of £12,460.  
 
The costs of the standard chemotherapy regimen for the patients who may be considered 
for treatment with HDC are estimated at between £1,980 and £2,970. This is based upon a 
regimen of six to nine courses of chemotherapy at £130 per course (£100 chemotherapy 
drugs and £30 anti-sickness drugs), with an additional day-case cost of £200 per course. 
Not included are any in-patient costs, such as admissions with infection or any orthopaedic 
procedures, incurred during standard therapy. 
 
These costs are for initial therapy only, and, therefore, likely to be underestimates. 
Significant other costs such as blood transfusions, orthopaedic admissions, radiotherapy, 
and analgesia are not included. These may well be lower for patients undergoing HDC, as 
the HDC procedure is followed by longer symptom-free periods and improved performance 
status. 
 
3.2.2  Long-term resource use for myeloma patients 
 
There is very little evidence available quantifying long-term resource use for myeloma 
patients. The only available published study considering cost-effectiveness of HDC for 
myeloma is reported by Henon et al.,
15
  comparing costs and outcomes of 12 patients with 
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Grade III myeloma treated with HDC and PBCT with 10 similar patients undergoing 
conventional chemotherapy. Eight of the 10 patients undergoing conventional chemotherapy 
died within one year of initial chemotherapy (range 3-12 months). During this time they were 
discharged from hospital for short periods only and their average cumulative hospitalisation 
was 4.8 months. The remaining two patients died of relapse two and four years from initial 
chemotherapy. Patients undergoing HDC with PBCT stayed in hospital for a median time of 
28 days from the start of conditioning. One patient died of procedure-related toxicity and 
eight others achieved complete remission, of whom two died of unrelated causes. Four were 
still in unmaintained complete remission with a median follow-up of four years. 
 
This study does not consider adequate numbers to provide cost estimates, but does 
demonstrate the difference in resource use for the two groups, with the conventional 
chemotherapy patients gaining little in terms of reasonable quality life. 
 
Ideally, it would be possible to quantify these ongoing costs via primary research of patient 
records and Patient Information System (PIS) data, comparing resource usage for patients 
undergoing HDC with those receiving conventional chemotherapy. Although it was possible 
to examine a small number of patient records, a complete analysis of lifetime costs of each 
group is not realistically possible for several reasons: 
 
 records are not available for patients who have died; 
 of the 10 autologous transplants which have taken place within Central Sheffield 
University Hospitals NHS Trust since 1989, five were in the past year and, thus, have no 
long-term follow-up available; 
 an accurate picture of typical resource use would need a larger volume of records as 
patient requirements vary significantly. 
 
PIS data were also unable to provide clear information regarding the ongoing hospital 
resource use for myeloma patients: 
 
 the secondary diagnosis code of myeloma is frequently omitted for orthopaedic 
admissions; 
 long-term follow-up would require analysis of several years’ data; 
 it is difficult to differentiate between patients undergoing HDC and those receiving 
standard chemotherapy from the procedure codes used. 
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Consideration of long-term follow-up costs is likely to reduce the marginal cost of treatment 
for HDC, as patients treated with HDC will cost less to support than those receiving 
conventional chemotherapy. Due to the paucity of data available, it has not been possible to 
quantify the differences in resource use for the two treatment groups. However, the reduced 
marginal difference will result in a lower cost per life year gained (LYG). 
 
If quality of life issues are included, the cost-effectiveness of HDC will improve considerably 
as HDC patients will typically have a longer period in remission during which they will benefit 
from excellent quality of life and return to previous working status. Clinical opinion suggests 
that the incorporation of quality of life values into economic analyses will increase the benefit 
of HDC and provide a quality adjusted cost per LYG estimate which is considerably lower 
than that suggested by the trial data alone. 
 
Therefore, the most that can currently be said on the basis of clinical observation and the 
results of reported case series is that it is likely that, after transplantation, HDC patients will 
cost less to support than conventional patients. However, it is important to stress that, even 
without these costs included, the economic argument for HDC is a positive one. 
 
3.3 Cost-effectiveness of High Dose Chemotherapy for Multiple Myeloma 
 
In considering the cost-effectiveness of HDC in multiple myeloma, the overall survival 
benefits for all patients (as discussed in Section 3.1) are compared with the implied marginal 
costs. The marginal survival benefit, as derived from the trial alone, is shown in Table 7, 
while the projected one and five year benefits derived from long-term follow-up data are 
considered in the sensitivity analysis.  
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Table 7 Cost-effectiveness of HDC in Multiple Myeloma: Trial Based Data 
Cost-Effectiveness Based 
on Trial Data Only  
(60 Months) 
Standard 
Chemotherapy 
High Dose 
Chemotherapy 
Marginal 
Survival 
Analysis 
Therapy cost £1,980 £12,460 £10,480 
 
Survival (area under the 
curve estimate)  
36 months 44 months 8 months 
 3.0 LYG 3.7 LYG 0.7 LYG 
Marginal cost per LYG - - £14,970 
 
Based on this analysis, the marginal survival benefit of HDC is predicted to be 0.7 years and 
the increase in treatment cost to be £10,480. This translates into a cost of £14,970 per LYG. 
 
3.4.  Sensitivity Analyses 
 
3.4.1.  Long-term Projected Benefits 
 
The above estimates consider benefits accrued during the five year trial period only. 
However, there may be further potential long-term gains for some patients receiving HDC 
when compared to standard therapy.  
 
At present there are no randomised trial data which quantitate such long-term outcomes. 
Non-randomised follow-up data from a single centre study reported by Cunningham,  
et al. (1994)
25
 have been examined, therefore, to estimate these putative long-term benefits. 
The outcomes in this study were comparable to those of the IFM trial (five year survival 
quoted at 15% for conventional chemotherapy and 45% for HDC).  
 
The results were reported at six years
13
 and 10 years.
29
 The most pessimistic scenario for 
one year follow-up is that the conventional arm retains the same benefits at six years as at 
five, and overall survival for the HDC is equivalent to that reported by Cunningham et al.
25
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In order to calculate potential benefits at 10 years, an assumption has been made of a 5% 
10 year survival with conventional therapy
31
 and 15% survival at 10 years for the HDC arm 
as reported by Powles et al.
29
 
 
Attempts to produce similar estimates for event-free survival at 10 years are limited by the 
fact that disease progression will have occurred in most, if not all, patients receiving both 
conventional chemotherapy and HDC. 
 
Consideration is given to the additional potential benefits based upon non-randomised trial 
results at one year and five year follow-up data; the marginal survival benefits increase and 
further reduce the estimated cost per LYG. 
 
Figure 9 One Year Projected Survival Benefits of HDC over Standard 
Chemotherapy 
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Figure 10 Five Year Projected Survival Benefits of HDC over Standard 
Chemotherapy 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8  Comparative Survival Benefits from the Cunningham
25
 Study 
Forward Projection of 
End of Trial Benefits 
Survival Benefit  
(Months) 
LYG 
1 year 11 (48 cf. 37 months) 0.9 
5 year 20 (60 cf. 40 months) 1.7 
 
Table 9 Cost-effectiveness of High Dose Chemotherapy in Multiple Myeloma: 
  Extended 1 Year Benefits Assumed 
Cost-effectiveness 
Including One Year 
Projected Benefits 
 
Standard 
Chemotherapy 
High Dose 
Chemotherapy 
Marginal 
Survival 
Analysis 
Therapy  cost £1,980 £12,460 £10,480 
 
Survival (Area Under the 
Curve estimate)  
37 months 48 months 11 months 
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 3.1 LYG 4.0 LYG 0.9 LYG 
 
Marginal cost per LYG 
 
- 
 
- 
 
£11,640 
Table 10 Cost-effectiveness of High Dose Chemotherapy in Multiple Myeloma: 
  Extended 5 Year Benefits Assumed. 
Cost-effectiveness 
Including Five Year 
Projected Benefits 
 
Standard 
Chemotherapy 
High Dose 
Chemotherapy 
Marginal 
Survival Analysis 
Therapy  cost £1,980 £12,460 £10,480 
 
Survival (area under the 
curve estimate)  
40 months 60 months 20 months 
 3.3 LYG 5.0 LYG 1.7 LYG 
 
Marginal Cost per LYG 
 
- 
 
- 
 
£6,160 
 
3.4.2  Sensitivity of Cost Per Life Year Gained to Costs of HDC and Marginal Clinical 
 Benefits 
The following sensitivity analyses are based upon the results reported during the IFM trial 
only. To examine 'best' and 'worst' case scenarios, costs for HDC ranging from £9,000 (the 
basic HDC cost without additional drug costs) to £20,000 have been explored. The effects of 
a reduction in clinical benefits to only half those reported in the trial have also been 
considered. 
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Figure 11  Sensitivity of Cost per LYG in Multiple Myeloma 
Sensitivity of Cost per LYG to HDC Cost and Marginal Clinical Benefit
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 Even with the cost of HDC increased to £20,000, the cost per LYG does not exceed 
£25,000.  
 Assuming the clinical benefits to be 50% lower than those reported in the trial, the cost 
per LYG increases to around £37,000.  
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4. OPTIONS FOR PURCHASERS AND PROVIDERS 
 
High Dose Chemotherapy is feasible in about 30% of patients with multiple myeloma. Such 
therapy increases remission rates, improves event-free survival and overall survival and 
results in improved quality of life. At present randomised controlled trial data, indicating a 
benefit for single transplantation, are available from a single trial, whilst the role of double 
transplant procedures is under investigation. 
 
The options for purchasers can be summarised as follows: 
 
Single transplantation 
 
1. Purchase conventional chemotherapy until the MRC trial reports (N.B. this would 
accentuate recruitment problems already experienced by the MRC trial and would delay 
reporting);  
2. Enrol suitable patients into the MRC trial; 
3. Purchase HDC for suitable patients: 
 allogeneic transplant for those aged <50  with HLA-identical sibling donor; 
 autologous transplant for those with a health status equivalent to, or better than, an 
average 65 year old, with good performance status, stage II/III disease. 
4. Purchase HDC for all myeloma patients (this is currently not justified with no benefit 
shown for older patients). 
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5. DISCUSSION AND CONCLUSIONS 
 
Due to the small number of patients involved, the evidence for the use of HDC in myeloma 
patients is based around one randomised trial and several small observational studies. 
These clearly indicate benefits in terms of survival, event-free survival and improved quality 
of life for a sub-set of myeloma patients.  
 
HDC has already been accepted by some as standard treatment, but there are trials 
ongoing to quantify further the benefits and explore options for further treatment, i.e. the use 
of double transplants. 
 
Draft EBMT guidelines recommend autologous transplantation for patients under 65 years 
of age who respond to first-line treatment for stages II and III. Allogeneic transplantation has 
been recommended for patients who respond to first-line treatment or before second-line 
treatment for patients who do not respond to first-line treatment. Allogeneic transplantation 
is only recommended in the EBMT guidelines for patients up to the age of 55 for whom a 
suitable donor can be found. 
 
There is an Health Technology Assessment (HTA) report in progress which considers the 
evidence for HDC in a range of cancers, including a short section on myeloma. At the time 
of writing this report, the HTA report was in the process of publication. However, a summary 
of its draft conclusions has been made available to the authors. 
 
These draft conclusions recommend participation in trials
14,28
 as they do not consider it 
possible at this stage to comment reliably on the efficacy of HDC with autologous 
transplantation. However, the basis for their reservations on the use of HDC in myeloma is 
not explained, although it is likely to be because only a single randomised trial is available. 
Allogeneic transplantations are considered an experimental therapy. 
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6.  USE OF HIGH DOSE CHEMOTHERAPY IN THE TREATMENT OF MULTIPLE  MYELOMA: SUMMARY MATRIX 
 
 
 
PATIENT GROUP PATIENT CRITERIA 
(GUIDELINES NOT PROTOCOLS) 
ESTIMATED 
FUTURE 
ACTIVITY 
OPPORTUNITY 
FOR COST 
SAVING 
AUDIT POINTS EFFECTS THAT COULD BE 
EXPECTED IN RELATION 
TO STARTING POINT 
 
COST-EFFECTIVENESS 
 
Newly diagnosed 
multiple myeloma 
patients. 
 
 
 
 
 
 
 
 
 
Patients who have a health status 
equivalent to, or better than, an average 
65 year old. 
 
Expected  10 
cases per 
annum for 
‘typical’ district 
of 500,000 pop. 
 
Reductions in 
hospital 
admissions, blood 
transfusions, 
analgesia, palliative 
radiotherapy etc. 
 
Overall  
survival, event-
free survival. 
 
Increased event-free survival 
and overall survival, potential  
of achieving cure. 
 
Projected 0.7 LYG per 
patient (minimum)  
 
Marginal cost per LYG of initial 
treatment of £14,970 
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